Markettelegraph.com: Markettelegraph.com Profiles HearAtLast Holdings, Inc. & Pluristem Therapeutics Inc.

HearAtLast Holdings, Inc. (PINKSHEETS: HRAL); Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT)

MarketTelegraph.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our FREE newsletter. Please follow our thread on www.twitter.com at StockProfilerUS

Stock Profiler is pleased to introduce HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.

-------------------------------------------

HearAtLast Holdings, Inc. closed at $0.0437 Tuesday, trading 195,900 shares.

Company News- October 13, 2009: HearAtLast Prepares to Release Quarterlies and Market Analysis From Harbinger Imminent

HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) the management team is pleased to have announced the imminent release of quarterly statements and a detailed outlook of the Hearing Health Care industry provided by the Harbinger Report yesterday.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About HearAtLast

HearAtLast Holdings, Inc. is a Nevada corporation that owns and operates its wholly owned subsidiary of hearing stores co-located within select Wal-Mart stores throughout Canada. Their chain of hearing stores specializes in the sale of digital hearing aids and testing services. The Company is the affordable hearing solution for Canadians, combining the most sought after retail space in North America with convenience and location. For more information please visit www.hearatlast.com.

-------------------------------------------

Pluristem Therapeutics Inc. closed at $1.15 Tuesday, trading 58,600 shares.

Company News- October 14, 2009: Pluristem Therapeutics Will Present at the New England-Israel Life Sciences Summit

Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT) announced earlier today that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Pluristem

Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.

See our product animation on YouTube: Animation, the content of which is not part of this press release.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. MarketTelegraph.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.fastmoneytalk.com, www.associatesfortune.com, www.thewallstreetleader.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market Wire, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes, Hearing Loss, Hearing Aids, Medical Devices, Wal-Mart

CONTACT: Markettelegraph.com Tel: +1 603 424 4420 e-mail: info@stockprofiler.us WWW: http://www.markettelegraph.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: advisor, aids, biotechnology, broker, canada, ceo, clinical, community, dax, dealer, e-mail, england, euro, finance, health, investment, investment opinion, israel, manufacturing, market, media, medical, nevada, north america, retail, securities, small cap, technology, track, web